Century Therapeutics Inc
NASDAQ:IPSC

  • LAST PRICE
    1.3300
  • TODAY'S CHANGE (%)
    0.0700 (5.5556%)
  • Bid / Lots
    1.3200/ 10
  • Ask / Lots
    1.3700/ 9
  • Open / Previous Close
    1.2600 / 1.2600
  • Day Range
    1.2500
    1.4300
  • 52 Week Range
    1.1400
    5.5100
  • Volume
    556,661

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 8 hours ago by MT Newswires
      Companies Mentioned: IPSC
      12:11 PM EST, 11/05/2024 (MT Newswires) -- Century Therapeutics (IPSC) shares were up more than 8% in recent Tuesday trading after the company reported Q3 results that beat market expectations. The firm posted a Q3 net loss of $0.37 per diluted shar...

    • 11 hours ago by MT Newswires
      Companies Mentioned: IPSC
      09:05 AM EST, 11/05/2024 (MT Newswires) -- ...

    • 11 hours ago by Dow Jones
      Companies Mentioned: IPSC

      212-600-1902
      Century Therapeutics, Inc Condensed Balance Sheets (unaudited, in thousands) September 30, December 31, Assets 2024 2023 Current Assets: $ $ Cash and cash equivalents 52,593 47,324 Short-term investments 145,519 125,414 Prepaid expenses and other current assets 7,897 4,256 ------------ ----------- Total current assets 206,009 176,994 Property and equipment, net 65,284 71,705 Operating lease right-of-use assets, net 28,828 20,376 Long-term investments 46,565 89,096 Goodwill 4,727 - Intangible assets 33,800 - Other long-term assets 3,404 2,520 ------------ ----------- Total assets $ 388,617 $ 360,691 ============ =========== Liabilities, convertible preferred stock, and stockholders' equity Current liabilities: Accounts payable $ 2,598 $ 2,741 Accrued expenses and other liabilities 13,653 10,733 Deferred revenue, current 3,569 4,372 ------------ ----------- Total current liabilities 19,820 17,846 Operating lease liability, noncurrent 50,837 46,658 Other long-term liabilities 20 56 Deferred revenue 109,768 111,381 Contingent consideration liability 8,983 - Deferred tax liability 3,503 - ------------ ----------- Total liabilities 192,931 175,941 ------------ ----------- Stockholders' equity Common stock 9 6 Additional paid-in capital 941,185 840,407 Accumulated deficit (746,266) (655,771) Accumulated other comprehensive loss 758 108 ------------ ----------- Total stockholders' equity 195,686 184,750 ------------ ----------- Total liabilities and stockholders' equity $ 388,617 $ 360,691 ============ =========== Century Therapeutics, Inc Condensed consolidated statements of operations (unaudited, in thousands, except share and per share amounts) Three Three Months Months Nine Months Nine Months Ended Ended Ended Ended September September September September 30, 30, 2024 30, 2023 30, 2024 2023 ----------- ----------- ----------- ------------- Collaboration Revenue $ 791 $ 148 $ 2,416 $ 1,967 Operating Expenses Research and development 27,228 22,788 77,869 70,414 General and administrative 8,352 8,986 25,400 26,117 In-process research and development - 4,000 - 4,000 Impairment on long-lived assets - - - 4,220 ---------- ---------- ---------- ---------- Total operating expenses 35,580 35,774 103,269 104,751 ---------- ---------- ---------- ---------- Loss from operations (34,789) (35,626) (100,853) (102,784) Interest expense - - - (540) Interest income 3,305 3,486 10,126 9,167 Other income, net 250 12 248 (368) ---------- ---------- ---------- ---------- Loss before provision for income taxes (31,234) (32,128) (90,479) (94,525) Benefit (provision) for income taxes 8 (592) (14) (2,750) Net Loss $ (31,226) $ (32,720) $ (90,493) $ (97,275) ========== ========== ========== ========== Unrealized gain (loss) on investments 1,075 (95) 622 1,157 Foreign currency translation adjustment gain (loss) (8) (2) 28 (1) ---------- ---------- ---------- Comprehensive loss $ (30,159) $ (32,817) $ (89,843) $ (96,119) ========== ========== ========== ========== Net loss per common share - Basic and Diluted (0.37) (0.55) (1.18) (1.65) ========== ========== ========== ========== Weighted average common shares outstanding 84,704,352 59,448,229 76,394,266 59,087,374 ========== ========== ========== ==========

    • 11 hours ago by Dow Jones
      Companies Mentioned: IPSC

    • 11 hours ago by Dow Jones
      Companies Mentioned: IPSC

      Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

      -- Company to share preclinical data across diverse pipeline of iNK, <GAMMA> iT, and <ALPHA><BETA> iT cell therapy programs for oncology and autoimmune disease (AID) --

Peers Headlines